chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Migraine
Clinical narrative: Terrible migraines; Dizzyness; . This spontaneous case was reported by an other and describes the occurrence of MIGRAINE (Terrible migraines) and DIZZINESS (Dizzyness) in a 30-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History Information was reported.     On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced MIGRAINE (Terrible migraines) and DIZZINESS (Dizzyness). At the time of the report, MIGRAINE (Terrible migraines) had not resolved and DIZZINESS (Dizzyness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications reported.  No treatment information was provided. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 16-Jul-2021 and was forwarded to Moderna on 16-Jul-2021.    . This spontaneous case was reported by an other and describes the occurrence of MIGRAINE (Terrible migraines) and DIZZINESS (Dizzyness) in a 30-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History Information was reported.     On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced MIGRAINE (Terrible migraines) and DIZZINESS (Dizzyness). At the time of the report, MIGRAINE (Terrible migraines) had not resolved and DIZZINESS (Dizzyness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications reported.  No treatment information was provided.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia
Clinical narrative: Debilitating muscle soreness; This spontaneous case was reported by an other and describes the occurrence of MYALGIA (Debilitating muscle soreness) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MYALGIA (Debilitating muscle soreness). At the time of the report, MYALGIA (Debilitating muscle soreness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant products was provided by the reporter.  No treatment information was provided by the reporter.
Sex: U
Vaccine: COVID19
Symptoms: Anosmia, Body temperature, COVID-19, Cough, Nasopharyngitis
Clinical narrative: COVID-19; Cold symptoms; Cough; Loss of smell; Temp 100.6; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19), NASOPHARYNGITIS (Cold symptoms), COUGH (Cough), ANOSMIA (Loss of smell) and PYREXIA (Temp 100.6) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Jul-2021, the patient experienced COVID-19 (COVID-19), NASOPHARYNGITIS (Cold symptoms), COUGH (Cough), ANOSMIA (Loss of smell) and PYREXIA (Temp 100.6). At the time of the report, COVID-19 (COVID-19), NASOPHARYNGITIS (Cold symptoms), COUGH (Cough), ANOSMIA (Loss of smell) and PYREXIA (Temp 100.6) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 15-Jul-2021, Body temperature: 100.6 (High) Temp 100.6. On 15-Jul-2021, SARS-CoV-2 test: positive (Positive) Tested positive for COVID.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.  Teatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 30-Jul-2021: Non Significant follow up - Patient initial updated.
Sex: U
Vaccine: COVID19
Symptoms: Pyrexia, SARS-CoV-2 test
Clinical narrative: COVID-19; Cold symptoms; Cough; Loss of smell; Temp 100.6; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19), NASOPHARYNGITIS (Cold symptoms), COUGH (Cough), ANOSMIA (Loss of smell) and PYREXIA (Temp 100.6) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Jul-2021, the patient experienced COVID-19 (COVID-19), NASOPHARYNGITIS (Cold symptoms), COUGH (Cough), ANOSMIA (Loss of smell) and PYREXIA (Temp 100.6). At the time of the report, COVID-19 (COVID-19), NASOPHARYNGITIS (Cold symptoms), COUGH (Cough), ANOSMIA (Loss of smell) and PYREXIA (Temp 100.6) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 15-Jul-2021, Body temperature: 100.6 (High) Temp 100.6. On 15-Jul-2021, SARS-CoV-2 test: positive (Positive) Tested positive for COVID.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.  Teatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 30-Jul-2021: Non Significant follow up - Patient initial updated.
Sex: M
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: beyond the 42 day window; missed second dose,first dose given to patient 28MAY2021 was told second dose can be given anytime; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (beyond the 42 day window; missed second dose,first dose given to patient 28MAY2021 was told second dose can be given anytime) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 050C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 28-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-May-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (beyond the 42 day window; missed second dose,first dose given to patient 28MAY2021 was told second dose can be given anytime). At the time of the report, PRODUCT DOSE OMISSION ISSUE (beyond the 42 day window; missed second dose,first dose given to patient 28MAY2021 was told second dose can be given anytime) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No treatment medications were reported.   Most recent FOLLOW-UP information incorporated above includes: On 16-Jul-2021: Follow-up received on 16 Jul 2021. updated reporter details, product details added.
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: Lethargy, Somnolence
Clinical narrative: It put him to sleep for 14 hours, woke up for an hour and went back to sleep for 5 more hours,  just want to sleep; Very lethargic; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of SOMNOLENCE (It put him to sleep for 14 hours, woke up for an hour and went back to sleep for 5 more hours,  just want to sleep) and LETHARGY (Very lethargic) in a 77-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 033C21A and 043B21A) for COVID-19 vaccination.     Concurrent medical conditions included Memory disturbance (Patient is taking memory pill). Concomitant products included APOAEQUORIN (PREVAGEN [APOAEQUORIN]) for Memory disturbance, SERTRALINE, LOSARTAN, ATORVASTATIN, VITAMIN D NOS, FAMOTIDINE, FISH OIL, TOPIRAMATE, ACETYLSALICYLIC ACID (BABY ASPIRIN) and MULTIVITAMIN [VITAMINS NOS] for an unknown indication.   On 16-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 20-May-2021, the patient experienced SOMNOLENCE (It put him to sleep for 14 hours, woke up for an hour and went back to sleep for 5 more hours,  just want to sleep) and LETHARGY (Very lethargic). The patient was treated with IRON for Iron supplementation, at an unspecified dose and frequency and ASCORBIC ACID (VIT C) for Vitamin C supplementation, at an unspecified dose and frequency. At the time of the report, SOMNOLENCE (It put him to sleep for 14 hours, woke up for an hour and went back to sleep for 5 more hours,  just want to sleep) and LETHARGY (Very lethargic) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Action taken with mRNA-1273 in response to the events was not applicable.  The patient consulted his Doctor who did a CT scan of his brain as well as checked his B12 and Iron levels.
Sex: U
Vaccine: COVID19
Symptoms: Product temperature excursion issue
Clinical narrative: administered to patient(s) after experiencing a temperature excursion; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (administered to patient(s) after experiencing a temperature excursion) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 048C21A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (administered to patient(s) after experiencing a temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (administered to patient(s) after experiencing a temperature excursion) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.   No treatment information was provided. Reporter asked for accurate expiration date and time for unpunctured (thawed) moderna vaccine which was out of temperature (~ 66 degrees) at 10:30 pm on 12-JUL-2021, as vaccine was back in good temperature at 10:32 am on 13-JUL-2021, and also asked whether new expiration date is on 13-OCT-2021 t 10:30 pm ?
Sex: U
Vaccine: COVID19
Symptoms: Influenza
Clinical narrative: side effects that are like the flu; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA (side effects that are like the flu) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INFLUENZA (side effects that are like the flu). At the time of the report, INFLUENZA (side effects that are like the flu) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Sex: M
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: The patient is on day 70 since the date of the first vaccination; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (The patient is on day 70 since the date of the first vaccination) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 001C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 07-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (The patient is on day 70 since the date of the first vaccination). At the time of the report, PRODUCT DOSE OMISSION ISSUE (The patient is on day 70 since the date of the first vaccination) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication details was provided. No treatment medication details was provided.
Sex: U
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: 2nd dose way too late beyond the window time (42 days); This spontaneous case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2nd dose way too late beyond the window time (42 days)) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Jul-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2nd dose way too late beyond the window time (42 days)). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2nd dose way too late beyond the window time (42 days)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported. No treatment information was provided.
Sex: M
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: A patient who received the first dose of the Moderna COVID-19 vaccine in February did not receive their second dose till date, more than 35 days past the first dose.; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (A patient who received the first dose of the Moderna COVID-19 vaccine in February did not receive their second dose till date, more than 35 days past the first dose.) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    In February 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (A patient who received the first dose of the Moderna COVID-19 vaccine in February did not receive their second dose till date, more than 35 days past the first dose.). At the time of the report, PRODUCT DOSE OMISSION ISSUE (A patient who received the first dose of the Moderna COVID-19 vaccine in February did not receive their second dose till date, more than 35 days past the first dose.) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications reported. No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 19-Jul-2021: Follow-up received on 19-Jul-2021 and does not contain any new information.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Did not get 2nd dose on time; This spontaneous case was reported by an other health care professional and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Did not get 2nd dose on time) in a 24-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 22-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Jul-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Did not get 2nd dose on time). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Did not get 2nd dose on time) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.   Description of Event or Problem: the HCP stated that the patient was unable to make it hence did not get the 2nd dose on time. No  concomitant medication provided by the reporter. no treatment information provided by the reporte
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Incontinence, Pyrexia
Clinical narrative: Moderna fever second night; Moderna fever second night; vaccine causing incontinence; This spontaneous case was reported by a consumer and describes the occurrence of INCONTINENCE (vaccine causing incontinence), the first episode of PYREXIA (Moderna fever second night) and the second episode of PYREXIA (Moderna fever second night) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003C21A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 (nasal Test) on 26-Jan-2021 and Incontinence (2 MONTHS) in October 2019. Concurrent medical conditions included Penicillin allergy. Concomitant products included ATORVASTATIN, COLECALCIFEROL (VIT D [COLECALCIFEROL]) and OMEPRAZOLE from 04-Jun-2021 to an unknown date for an unknown indication.   On 10-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 11-May-2021, the patient experienced the first episode of PYREXIA (Moderna fever second night). In May 2021, the patient experienced INCONTINENCE (vaccine causing incontinence). On 16-Jun-2021, the patient experienced the second episode of PYREXIA (Moderna fever second night). At the time of the report, INCONTINENCE (vaccine causing incontinence) and the last episode of PYREXIA (Moderna fever last night) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 26-Jan-2021, COVID-19: positive (Positive) Positive.          No Treatment Medication was provided.   Most recent FOLLOW-UP information incorporated above includes: On 29-Jul-2021: ADR : Reporter contact information, vaccination date, patient demographics updated
Age: 26.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Headache, Myalgia, Pyrexia
Clinical narrative: This spontaneous case reported by a patient's family member/friend, describes the occurrence of pyrexia (fever), chills, arthralgia (joint pain), myalgia (muscle pain) and headache in a 26-year-old male patient who received mRNA-1273 (Moderna COVID-19 vaccine, batch/lot# 037C21A) for COVID-19 immunization. No medical history reported. On Jul 15, 2021, patient received the second dose of mRNA-1273 (Moderna COVID-19 vaccine), intramuscular; 1 dosage form. On an unknown date, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), intramuscular; 1 dosage form. On Jul 16, 2021, patient experienced pyrexia (fever), chills, arthralgia (joint pain), myalgia (muscle pain) and headache. At the time of the report, pyrexia (fever), chills, arthralgia (joint pain), myalgia (muscle pain) and headache) outcome: unknown. No concomitant medication or treatment information provided.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia
Clinical narrative: Painful, tender and sore right ankle; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (Painful, tender and sore right ankle) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 048B21A and 005C21A) for COVID-19 vaccination.     The patient's past medical history included Ankle sprain (severe sprain to right ankle but it healed completely) in 2012.   On 24-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced ARTHRALGIA (Painful, tender and sore right ankle). The patient was treated with NAPROXEN at an unspecified dose and frequency; NAPROXEN SODIUM (ALEVE) at an unspecified dose and frequency and Physical therapy (Physical therapy 2-3 times a week) for Arthralgia. At the time of the report, ARTHRALGIA (Painful, tender and sore right ankle) had not resolved.            No concomitant medications were provided.  Additional treatment details include acupuncture and ice pack application.   Most recent FOLLOW-UP information incorporated above includes: On 28-Jul-2021: Event outcome updated, treatment information added
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Accidental underdose
Clinical narrative: liquid leaked out of the site of injection after vaccination/The patient is worried and scared, don't know if  received full dose; This spontaneous case was reported by a consumer and describes the occurrence of ACCIDENTAL UNDERDOSE (liquid leaked out of the site of injection after vaccination/The patient is worried and scared, don't know if  received full dose) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 049C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Jun-2021, the patient experienced ACCIDENTAL UNDERDOSE (liquid leaked out of the site of injection after vaccination/The patient is worried and scared, don't know if  received full dose).        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Age: 52.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test, SARS-CoV-2 test positive
Clinical narrative: PCR test positive; Rapid test positive; This spontaneous case was reported by a consumer and describes the occurrence of SARS-COV-2 TEST POSITIVE (Rapid test positive) and SARS-COV-2 TEST POSITIVE (PCR test positive) in a 52-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 036B21A and 045A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 13-Jul-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced SARS-COV-2 TEST POSITIVE (Rapid test positive). On 14-Jul-2021, the patient experienced SARS-COV-2 TEST POSITIVE (PCR test positive). At the time of the report, SARS-COV-2 TEST POSITIVE (Rapid test positive) and SARS-COV-2 TEST POSITIVE (PCR test positive) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 13-Jul-2021, SARS-CoV-2 test: positive Positive. On 14-Jul-2021, SARS-CoV-2 test: positive Positive.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant product reported by reporter. No treatment medication reported by reporter. Preferred method for safety follow up was phone.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Cough, Fatigue, Headache, Illness
Clinical narrative: started having a fever.; headache; chest discomfort; nasal congestion; coughing; nausea; sore arm; fatigue; sick the whole day; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (sick the whole day), CHEST DISCOMFORT (chest discomfort), NASAL CONGESTION (nasal congestion), COUGH (coughing) and NAUSEA (nausea) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 003A21A and 012L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 22-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 24-Mar-2021, the patient experienced ILLNESS (sick the whole day), NAUSEA (nausea), LIMB DISCOMFORT (sore arm) and FATIGUE (fatigue). On 12-Jul-2021, the patient experienced CHEST DISCOMFORT (chest discomfort), NASAL CONGESTION (nasal congestion), COUGH (coughing) and HEADACHE (headache). On an unknown date, the patient experienced PYREXIA (started having a fever.). On 24-Mar-2021, ILLNESS (sick the whole day), LIMB DISCOMFORT (sore arm) and FATIGUE (fatigue) had resolved, NAUSEA (nausea) outcome was unknown. At the time of the report, CHEST DISCOMFORT (chest discomfort), NASAL CONGESTION (nasal congestion), COUGH (coughing), HEADACHE (headache) and PYREXIA (started having a fever.) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 15-Jul-2021, SARS-CoV-2 test: positive positive (Positive) positive.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications include over the counter allergy medications, not otherwise specified. No treatment medication details was reported.   This case was linked to MOD-2021-259111 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 16-Jul-2021: Significant follow up appended to AER
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Limb discomfort, Nasal congestion, Nausea, Pyrexia, SARS-CoV-2 test
Clinical narrative: started having a fever.; headache; chest discomfort; nasal congestion; coughing; nausea; sore arm; fatigue; sick the whole day; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (sick the whole day), CHEST DISCOMFORT (chest discomfort), NASAL CONGESTION (nasal congestion), COUGH (coughing) and NAUSEA (nausea) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 003A21A and 012L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 22-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 24-Mar-2021, the patient experienced ILLNESS (sick the whole day), NAUSEA (nausea), LIMB DISCOMFORT (sore arm) and FATIGUE (fatigue). On 12-Jul-2021, the patient experienced CHEST DISCOMFORT (chest discomfort), NASAL CONGESTION (nasal congestion), COUGH (coughing) and HEADACHE (headache). On an unknown date, the patient experienced PYREXIA (started having a fever.). On 24-Mar-2021, ILLNESS (sick the whole day), LIMB DISCOMFORT (sore arm) and FATIGUE (fatigue) had resolved, NAUSEA (nausea) outcome was unknown. At the time of the report, CHEST DISCOMFORT (chest discomfort), NASAL CONGESTION (nasal congestion), COUGH (coughing), HEADACHE (headache) and PYREXIA (started having a fever.) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 15-Jul-2021, SARS-CoV-2 test: positive positive (Positive) positive.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications include over the counter allergy medications, not otherwise specified. No treatment medication details was reported.   This case was linked to MOD-2021-259111 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 16-Jul-2021: Significant follow up appended to AER
Sex: F
Vaccine: COVID19
Symptoms: Eye swelling, Foreign body reaction, Lip swelling, Skin reaction, Swelling face
Clinical narrative: foreign body reactions; dermatological filler Reactions / Reactions; Swelling came back on her eyes and lips; Eye swelling; Facial swelling right where she had fillers; This spontaneous case was reported by a patient and describes the occurrence of SWELLING FACE (Facial swelling right where she had fillers), LIP SWELLING (Swelling came back on her eyes and lips), EYE SWELLING (Eye swelling), FOREIGN BODY REACTION (foreign body reactions) and SKIN REACTION (dermatological filler Reactions / Reactions) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 016B21A and 001B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 18-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In May 2021, the patient experienced SWELLING FACE (Facial swelling right where she had fillers). In July 2021, the patient experienced LIP SWELLING (Swelling came back on her eyes and lips) and EYE SWELLING (Eye swelling). On an unknown date, the patient experienced FOREIGN BODY REACTION (foreign body reactions) and SKIN REACTION (dermatological filler Reactions / Reactions). The patient was treated with PREDNISONE for Adverse event, at a dose of UNK dosage form; CEFALEXIN (CEPHALEXINE) for Adverse event, at a dose of UNK dosage form and DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Adverse event, at a dose of UNK dosage form. At the time of the report, SWELLING FACE (Facial swelling right where she had fillers), LIP SWELLING (Swelling came back on her eyes and lips) and EYE SWELLING (Eye swelling) had not resolved and FOREIGN BODY REACTION (foreign body reactions) and SKIN REACTION (dermatological filler Reactions / Reactions) outcome was unknown.            No concomitant medications were provided.   Most recent FOLLOW-UP information incorporated above includes: On 16-Jul-2021: follow up received on 16-jul-21 with events added and outcome.
Age: 73.0
Sex: M
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: first dose < 25 days ago; This spontaneous case was reported by a nurse and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (first dose < 25 days ago) in a 73-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 939676 and 939676) for COVID-19 vaccination.     No Medical History information was reported.   On 01-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Jul-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In July 2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (first dose < 25 days ago). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (first dose < 25 days ago) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient did not experience any adverse event or reaction.  No concomitant medications were provided by the reporter.  Treatment information was not provided.
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Alopecia
Clinical narrative: Hair started to fall out; This spontaneous case was reported by a consumer and describes the occurrence of ALOPECIA (Hair started to fall out) in a 72-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 001A21A and 001A21A) for COVID-19 vaccination.     Concurrent medical conditions included Drug allergy (Patient has allergy to Ciprofloxacin.) and Drug allergy (Patient has allergy some generic drugs.). Concomitant products included COLECALCIFEROL (VITAMIN D3), LEVETIRACETAM (KEPPRA XR), BIOTIN, PROBIOTICS NOS and CIPROFLOXACIN for an unknown indication.   On 21-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 13-Jul-2021, the patient experienced ALOPECIA (Hair started to fall out). At the time of the report, ALOPECIA (Hair started to fall out) outcome was unknown.            Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 29-Jul-2021: received FU document it does not contain newinformation.
Sex: U
Vaccine: COVID19
Symptoms: Arthralgia, Back pain, Muscle spasms, Muscle tightness, Musculoskeletal chest pain
Clinical narrative: sore arm went on to be pain down left arm extending to left ring finger and middle finger; Pain down my left side ribs, pain over ribs; pain down my back; muscle tightness left side.; Neck pain muscle tightness left side.; cramps muscle pain over chest left rib area; muscle was standing up over 1 inch; pain is mild to extreme; Pain on my left shoulder turned into a muscle pain/cramp shoulder down my back lasting 12 hours; standard sore arm about 4-5 inches below the site; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore arm went on to be pain down left arm extending to left ring finger and middle finger), MUSCULOSKELETAL CHEST PAIN (Pain down my left side ribs, pain over ribs), BACK PAIN (pain down my back), MUSCLE TIGHTNESS (muscle tightness left side.) and NECK PAIN (Neck pain muscle tightness left side.) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 029L20A and 024M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (sore arm went on to be pain down left arm extending to left ring finger and middle finger), MUSCULOSKELETAL CHEST PAIN (Pain down my left side ribs, pain over ribs), BACK PAIN (pain down my back), MUSCLE TIGHTNESS (muscle tightness left side.), NECK PAIN (Neck pain muscle tightness left side.), MUSCLE SPASMS (cramps muscle pain over chest left rib area), SKIN MASS (muscle was standing up over 1 inch), PAIN (pain is mild to extreme), ARTHRALGIA (Pain on my left shoulder turned into a muscle pain/cramp shoulder down my back lasting 12 hours) and VACCINATION SITE PAIN (standard sore arm about 4-5 inches below the site). The patient was treated with METHYLPREDNISOLONE SODIUM SUCCINATE (METHYLPREDNISOLON [METHYLPREDNISOLONE SODIUM SUCCINATE]) at a dose of 21 tablets and ORPHENADRINE CITRATE at a dose of 100 milligram. At the time of the report, PAIN IN EXTREMITY (sore arm went on to be pain down left arm extending to left ring finger and middle finger), MUSCULOSKELETAL CHEST PAIN (Pain down my left side ribs, pain over ribs), BACK PAIN (pain down my back), MUSCLE TIGHTNESS (muscle tightness left side.), NECK PAIN (Neck pain muscle tightness left side.), MUSCLE SPASMS (cramps muscle pain over chest left rib area), SKIN MASS (muscle was standing up over 1 inch), PAIN (pain is mild to extreme), ARTHRALGIA (Pain on my left shoulder turned into a muscle pain/cramp shoulder down my back lasting 12 hours) and VACCINATION SITE PAIN (standard sore arm about 4-5 inches below the site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Sex: U
Vaccine: COVID19
Symptoms: Neck pain, Pain, Pain in extremity, Skin mass, Vaccination site pain
Clinical narrative: sore arm went on to be pain down left arm extending to left ring finger and middle finger; Pain down my left side ribs, pain over ribs; pain down my back; muscle tightness left side.; Neck pain muscle tightness left side.; cramps muscle pain over chest left rib area; muscle was standing up over 1 inch; pain is mild to extreme; Pain on my left shoulder turned into a muscle pain/cramp shoulder down my back lasting 12 hours; standard sore arm about 4-5 inches below the site; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore arm went on to be pain down left arm extending to left ring finger and middle finger), MUSCULOSKELETAL CHEST PAIN (Pain down my left side ribs, pain over ribs), BACK PAIN (pain down my back), MUSCLE TIGHTNESS (muscle tightness left side.) and NECK PAIN (Neck pain muscle tightness left side.) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 029L20A and 024M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (sore arm went on to be pain down left arm extending to left ring finger and middle finger), MUSCULOSKELETAL CHEST PAIN (Pain down my left side ribs, pain over ribs), BACK PAIN (pain down my back), MUSCLE TIGHTNESS (muscle tightness left side.), NECK PAIN (Neck pain muscle tightness left side.), MUSCLE SPASMS (cramps muscle pain over chest left rib area), SKIN MASS (muscle was standing up over 1 inch), PAIN (pain is mild to extreme), ARTHRALGIA (Pain on my left shoulder turned into a muscle pain/cramp shoulder down my back lasting 12 hours) and VACCINATION SITE PAIN (standard sore arm about 4-5 inches below the site). The patient was treated with METHYLPREDNISOLONE SODIUM SUCCINATE (METHYLPREDNISOLON [METHYLPREDNISOLONE SODIUM SUCCINATE]) at a dose of 21 tablets and ORPHENADRINE CITRATE at a dose of 100 milligram. At the time of the report, PAIN IN EXTREMITY (sore arm went on to be pain down left arm extending to left ring finger and middle finger), MUSCULOSKELETAL CHEST PAIN (Pain down my left side ribs, pain over ribs), BACK PAIN (pain down my back), MUSCLE TIGHTNESS (muscle tightness left side.), NECK PAIN (Neck pain muscle tightness left side.), MUSCLE SPASMS (cramps muscle pain over chest left rib area), SKIN MASS (muscle was standing up over 1 inch), PAIN (pain is mild to extreme), ARTHRALGIA (Pain on my left shoulder turned into a muscle pain/cramp shoulder down my back lasting 12 hours) and VACCINATION SITE PAIN (standard sore arm about 4-5 inches below the site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Age: 81.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site erythema, Peripheral swelling, Pyrexia
Clinical narrative: Swollen Right Arm; Fever; Red Injection Site on the Right Arm; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (Swollen Right Arm), PYREXIA (Fever) and INJECTION SITE ERYTHEMA (Red Injection Site on the Right Arm) in an 81-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 003A21A and 006M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Mar-2021, the patient experienced PERIPHERAL SWELLING (Swollen Right Arm), PYREXIA (Fever) and INJECTION SITE ERYTHEMA (Red Injection Site on the Right Arm). On 15-Mar-2021, PERIPHERAL SWELLING (Swollen Right Arm), PYREXIA (Fever) and INJECTION SITE ERYTHEMA (Red Injection Site on the Right Arm) had resolved.            No concomitant medications were reported. Treatment information was not provided by the reporter.   This case was linked to MOD-2021-022177 (Patient Link).
Age: 20.0
Sex: M
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: second dose later than 42 days; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (second dose later than 42 days) in a 20-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (second dose later than 42 days). At the time of the report, PRODUCT DOSE OMISSION ISSUE (second dose later than 42 days) had resolved.            No concomitant medications were provided. No treatment medications were provided.
Sex: U
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive
Clinical narrative: the pt that I reported was +covid post moderna vaccine #1; This spontaneous case was reported by a nurse and describes the occurrence of SARS-COV-2 TEST POSITIVE (the pt that I reported was +covid post moderna vaccine #1) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced SARS-COV-2 TEST POSITIVE (the pt that I reported was +covid post moderna vaccine #1). At the time of the report, SARS-COV-2 TEST POSITIVE (the pt that I reported was +covid post moderna vaccine #1) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test positive: positive (Positive) reported positive for covid post moderna vaccine..     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No treatment drug information provided. No concomitant drug information provided.    Reporter did not allow further contact
Sex: M
Vaccine: COVID19
Symptoms: Blood pressure measurement, Panic attack, Vaccination complication
Clinical narrative: "A bad reaction"; "Panic attacks"; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 16-Jul-2021 and was forwarded to Moderna on 16-Jul-2021.    This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION ("A bad reaction") and PANIC ATTACK ("Panic attacks") in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION ("A bad reaction") and PANIC ATTACK ("Panic attacks"). At the time of the report, VACCINATION COMPLICATION ("A bad reaction") and PANIC ATTACK ("Panic attacks") outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood pressure measurement: abnormal (abnormal) blood pressure going crazy.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication included unknown. Patient had COVID19 in January  No treatment information was provided
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Product storage error, Rash erythematous, Wrong technique in product usage process
Clinical narrative: red circle like a bump the size of a half dollar 2 inch in diameter and that is red; vaccine was frozen; vaccine was frozen; This spontaneous case was reported by a consumer and describes the occurrence of RASH ERYTHEMATOUS (red circle like a bump the size of a half dollar 2 inch in diameter and that is red), PRODUCT STORAGE ERROR (vaccine was frozen) and WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (vaccine was frozen) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 050c21a and 051c21a) for COVID-19 vaccination.     No Medical History information was reported.   On 15-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Jul-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 16-Jul-2021, the patient experienced RASH ERYTHEMATOUS (red circle like a bump the size of a half dollar 2 inch in diameter and that is red), PRODUCT STORAGE ERROR (vaccine was frozen) and WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (vaccine was frozen). On 16-Jul-2021, PRODUCT STORAGE ERROR (vaccine was frozen) and WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (vaccine was frozen) had resolved. At the time of the report, RASH ERYTHEMATOUS (red circle like a bump the size of a half dollar 2 inch in diameter and that is red) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were not reported. No treatment medications were not provided.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: Patient scheduled to receive 2nd dose of the vaccine 62 days after 1st dose; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Patient scheduled to receive 2nd dose of the vaccine 62 days after 1st dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 033B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Patient scheduled to receive 2nd dose of the vaccine 62 days after 1st dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Patient scheduled to receive 2nd dose of the vaccine 62 days after 1st dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment medications were reported.